Sandrock’s first month at Voyager sours as shares crumble on Levin, Paul’s move to step off the board

Kyle LaHucik

Senior Reporter

Voyager Therapeutics was able to poach Al Sandrock out of his very, very brief retirement from Biogen to right its wavering gene therapy ship after a rocky first nine years. But a month into his journey, two of Sandrock’s fellow board members don’t want to be reelected.

One of those is Voyager’s own co-founder and former CEO Steven Paul. The other is Mark Levin, the Millennium co-founder and an original member of Third Rock Ventures, the VC firm that launched Voyager in 2013.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Sandrock’s first month at Voyager sours as shares crumble on Levin, Paul’s move to step off the board

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

San­drock’s first month at Voy­ager sours as shares crum­ble on Levin, Paul’s move to step off the board

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Sandrock’s first month at Voyager sours as shares crumble on Levin, Paul’s move to step off the board

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs